Clinical benefit and toxicity of nivolumab plus ipilimumab in patients with advanced melanoma previously treated with checkpoint blockade inhibitors.

@inproceedings{Friedman2018ClinicalBA,
  title={Clinical benefit and toxicity of nivolumab plus ipilimumab in patients with advanced melanoma previously treated with checkpoint blockade inhibitors.},
  author={Claire Friedman and Jedd D. Wolchok and Michael A Postow and Alexander N Shoushtari and Margaret K. Callahan and Parisa Momtaz and Paul B Chapman},
  year={2018}
}
100Background: The combination of nivolumab and ipilimumab (nivo+ipi) prolongs progression-free survival in treatment-naive patients (pts) with advanced melanoma. However, the efficacy and tolerability of nivo+ipi in pts previously treated with checkpoint blockade inhibitors (CPI) are unknown. Methods: 19 pts previously treated with CPI (ipi or anti-PD-1 as single agents) were treated with nivo+ipi at MSKCC. Ipi (3mg/kg) and nivo (1mg/kg) were administered q3 weeks for 4 doses with the option… CONTINUE READING